RESEARCH ARTICLE

Poor efficacy of preemptive amoxicillin clavulanate for preventing secondary infection from Bothrops snakebites in the Brazilian Amazon: A randomized controlled clinical trial

Jacqueline A. G. Sachett¹,², Iran Mendonca da Silva¹,², Eliane Campos Alves¹,², Sâmella S. Oliveira¹,², Vanderson S. Sampaio¹,²,³, Fábio Francesconi do Vale¹,⁴, Gustavo Adolfo Sierra Romero¹,², Marcelo Cordeiro dos Santos¹,², Hedylamar Oliveira Marques⁵, Mônica Colombini⁶, Ana Maria Moura da Silva⁷, Fan Hui Wen⁷, Marcus V. G. Lacerda¹,²,⁸, Wuelton M. Monteiro¹,²*, Luiz C. L. Ferreira¹,²

¹ Diretoria de Ensino e Pesquisa, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil, 2 Escola Superior de Ciências da Saúde, Universidade do Estado do Amazonas, Manaus, Brazil, 3 Núcleo de Sistemas de Informação, Fundação de Vigilância em Saúde do Amazonas, Manaus, Brazil, 4 Faculdade de Medicina, Universidade Federal do Amazonas, Manaus, Brazil, 5 Núcleo de Medicina Tropical, Faculdade de Medicina, Universidade de Brasília, Brasília, Brazil, 6 Diretoria de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil, 7 Divisão de Desenvolvimento Científico, Instituto Butantan, São Paulo, Brazil, 8 Instituto de Pesquisas Leónidas & Maria Deane, FIOCRUZ, Manaus, Brazil

* wueltonmm@gmail.com

Abstract

Background
Secondary bacterial infections from snakebites contribute to the high complication rates that can lead to permanent function loss and disabilities. Although common in endemic areas, routine empirical prophylactic use of antibiotics aiming to prevent secondary infection lacks a clearly defined policy. The aim of this work was to estimate the efficacy of amoxicillin clavulanate for reducing the secondary infection incidence in patients bitten by Bothrops snakes, and, secondarily, identify risk factors for secondary infections from snakebites in the Western Brazilian Amazon.

Methods and findings
This was an open-label, two-arm individually randomized superiority trial to prevent secondary infection from Bothrops snakebites. The antibiotic chosen for this clinical trial was oral amoxicillin clavulanate per seven days compared to no intervention. A total of 345 patients were assessed for eligibility in the study period. From this total, 187 accomplished the inclusion criteria and were randomized, 93 in the interventional group and 94 in the untreated control group. All randomized participants completed the 7 days follow-up period. Enzyme immunoassay confirmed Bothrops envenoming diagnosis in all participants. Primary outcome was defined as secondary infection (abscess and/or cellulitis) until day 7 after
admission. Secondary infection incidence until 7 days after admission was 35.5% in the intervention group and 44.1% in the control group [RR = 0.80 (95%CI = 0.56 to 1.15; p = 0.235)]. Survival analysis demonstrated that the time from patient admission to the onset of secondary infection was not different between amoxicillin clavulanate treated and control group (Log-rank = 2.23; p = 0.789). Secondary infections incidence in 7 days of follow-up was independently associated to fibrinogen >400 mg/dL [AOR = 4.78 (95%CI = 2.17 to 10.55; p<0.001)], alanine transaminase >44 IU/L [AOR = 2.52 (95%CI = 1.06 to 5.98; p = 0.037)], C-reactive protein >6.5 mg/L [AOR = 2.98 (95%CI = 1.40 to 6.35; p = 0.005)], moderate pain [AOR = 24.30 (95%CI = 4.69 to 125.84; p<0.001)] and moderate snakebites [AOR = 2.43 (95%CI = 1.07 to 5.50; p = 0.034)].

Conclusions/Significance
Preemptive amoxicillin clavulanate was not effective for preventing secondary infections from Bothrops snakebites. Laboratorial markers, such as high fibrinogen, alanine transaminase and C-reactive protein levels, and severity clinical grading of snakebites, may help to accurately diagnose secondary infections.

Trial registration
Brazilian Clinical Trials Registry (ReBec): RBR-3h33wy; UTN Number: U1111-1169-1005.

Author summary
Bothrops genus is responsible by 80–90% of the snakebites in the Brazilian Amazon, resulting in a subcutaneous and muscular lesion at the site of bite, which many times evolve to local complications, mostly secondary bacterial infections. In this region, late medical assistance is common and probably contributes to the high complication rates related to local necrosis and secondary bacterial infections, which can lead to permanent function loss and disabilities. Even with this high frequency, routine empirical use of antibiotics aiming to prevent secondary infection lacks a clearly defined protocol. In this work, we estimated the efficacy of amoxicillin clavulanate for reducing the secondary infection incidence in patients bitten by Bothrops snakes, and, identified factors related to secondary infections from snakebites. Amoxicillin clavulanate was not effective for preventing secondary infections from Bothrops snakebites, probably because of the resistance to β-lactam antibiotics in bacteria species commonly found infecting the snakebite site. This finding highlights the need of previous knowledge of the secondary infections epidemiology as a cornerstone in the preemptive antibiotics trials in snakebites. Laboratorial markers, such as high fibrinogen, alanine transaminase and C-reactive protein levels, and severity clinical grading of snakebites, may help to accurately diagnose secondary infections.

Introduction
Bothrops snakebites result in a subcutaneous and muscular lesion at the site of bite, which many times evolve to local complications [1–5]. In 2015, the Brazilian Ministry of Health recorded 18,741 snakebites across the country [6]. In this country, a higher incidence is
observed in the Brazilian region (37 cases/100,000 inhabitants). These values could be higher in remote areas of the Amazon because of the considerable case underreporting [7]. Snakebites are recorded mostly from remote rural or riverine areas, from where patients’ rescue to the health units is made exclusively by boat transportation, lasting several hours or even days [8–10]. Thus, late medical assistance is common and probably contributes to the high complication rates related to local necrosis [10–12] and secondary bacterial infections [10–15], that can lead to permanent function loss and disabilities [3,10,16–19]. It was suggested that secondary bacterial infections from snakebites are related to the oral and fangs microbiota of the perpetrating snake [20–26]. Besides, traditional treatment also contributes for the emergence of secondary infections, such as tourniquet use, local alternative medicines, incision and suction of the bite site [8,18,27]. These factors increase the development of expressive forms of secondary infection, which has been primarily diagnosed with identification of cellulitis or abscesses [12,13,22].

In the Brazilian Amazon, Bothrops atrox is the most important venomous snake, causing 80–90% of the snake envenomings [28]. Despite the wide geographic distribution in the Amazon, B. atrox venoms share the same family of toxins, as PIII and PI snake venom metalloproteinase, phospholipase A2, serine proteinase, cysteine-rich secretory protein, L-amino acid oxidase and C-type lectin-like [29,30] and are characterized by coagulant, hemorrhagic and proteolytic or acute inflammatory activities [31–33]. Spontaneous systemic bleeding and acute renal failure are common systemic complications from Bothrops envenomings [13,34]. Local envenomation range from a painless reddened injury to intense pain and swelling at the site of bite, starting minutes after the event. Enlargement of the regional lymph nodes draining the site of bite and bruising can also be observed some hours after bite, especially if patient delayed in reaching a health service [33,34]. In the first 24 hours, blistering and tissue necrosis may be evident. Cellulitis or abscess occurs mostly in the moderate or severe cases, generally as a polymicrobial infection. Gram-negative bacteria have been implicated in secondary bacterial infection, which frequency may vary according to region [35]. In Manaus, secondary bacterial infections were observed in around 40% of the Bothrops snakebites [13].

Several antimicrobial schemes were suggested for the treatment of secondary infections, but in general these recommendations were not based on good evidences from clinical trials [36,37]. For example, ampicillin/cephalosporin/cloxacillin [14,27], ciprofloxacin [15,22] and clindamycin [36,38,39] were previously used for secondary bacterial infections resulted from snakebites, with variable effectiveness. In the Amazon, basic information about the bacterial agents responsible by the wound infection is still lacking since secondary infection diagnosis is mostly based only from clinical features without microbiological confirmation. Although common in endemic areas, routine empirical prophylactic use of antibiotics aiming to prevent secondary infection lacks a clearly defined policy, leading to wasteful inappropriate antibiotic use, which is costly and may promote bacterial antibiotic resistance [22,40]. Preemptive treatment efficacy of oral chloramphenicol monotherapy in Bothrops snakebites [41] and intravenous chloramphenicol plus gentamicin in Crotalus snakebites [42] showed no statistical difference between patients treated and untreated groups. Nowadays, however, the Infectious Diseases Society of America (IDSA) guidelines for diagnosis and management of skin and soft-tissue infections indicate amoxicillin clavulanate to reduce complications by prevention of secondary infection from animal bites [38,39]. Evidence supporting this recommendation came from a clinical trial carried out with patients bitten by dogs [43], but efficacy of this regimen is still not available in snakebites.

The aim of this work was to estimate the efficacy of amoxicillin clavulanate for reducing the secondary infection incidence in patients bitten by Bothrops snakes, and, secondarily, identify associated factors for secondary infections from snakebites in the Western Brazilian Amazon.
Methods and materials

Ethics statement

Ethical approval was obtained from the Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD) (approval number 492.892/2013). Written informed consent was obtained from all participants prior to randomization. This study was registered in the Brazilian Clinical Trials Registry (ReBec): RBR-3h33wy and UTN Number: U1111-1169-1005.

Study design and participants

This was an open-label, two-arm individually randomized superiority trial to estimate the efficacy of the preemptive amoxicillin clavulanate administration compared to no intervention for preventing secondary infection from Bothrops snakebites. Clinical trial was performed at the Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD), in Manaus, Western Brazilian Amazon, from August 2014 to September 2016. This tertiary hospital is the reference in the Amazonas state for snakebites treatment. In Manaus, FMT-HVD is the only hospital unit that performs the distribution and administration of snakebite antivenom. At admission, Bothrops snakebites were diagnosed with basis in clinico-epidemiological characteristics of the patient and, when the patient brought the snake responsible by the envenomation, by its identification made by a trained biologist.

Sample size calculation was based on the mean of 240 snakebites/year attended at FMT-HVD, with an expected frequency of secondary infection of 40% [13], a 50% risk reduction of infection, at an 80% power and 5% of significance level and an 1:1 randomization ratio. Adding 10% of losses in the follow-up, a sample size of 186 participants was obtained, with 93 patients in the intervention group and 93 in the untreated group.

Eligibility, randomization and intervention

Patient was eligible if admitted to the hospital with less than 24 hours after the bite, without antivenom therapy in other hospital and without any sign of secondary infection at this time. Patients that used any antibiotic in the past 30 days, pregnant women or patients with previous history of allergic reactions to antibiotics were not included in this trial.

After application of eligibility criteria, the study pharmacist was contacted to obtain the allocation group to the patient. Randomization sequences with an allocation ratio of 1:1 were computer-generated by a random table, to the intervention group (preemptive amoxicillin clavulanate) or to the control group (no preemptive antibiotic prescription). All laboratory staff was blinded for treatment assignment. The antibiotic chosen for this trial was oral tablet amoxicillin clavulanate 875/125 mg to adults and 25 mg/kg/day to children twice per day for seven days, starting at the admission day.

Admission and follow-up procedures

After patient inclusion, demographic and epidemiological information was collected using a standardized questionnaire, including gender, age (in years), area of occurrence (urban or rural), anatomical site of the bite, work-related bite (yes or no), time elapsed from bite to medical assistance (in hours), walking after bite (in minutes), previous history of snakebite and pre-admission conduits (use of topical or oral medicines, use of tourniquet and other procedures). A detailed clinical and laboratorial characterization was also made at this time. Pain assessment was made using the Numerical Rating Scale, with values rating from 1 to 10 [44]; pain was further classified as absent (rate 0), mild (rated from 1 to 3), moderate (rated from 4 to 7) and severe (rated from 8 to 10). Edema was classified as absent, mild (affecting 1–2 limb
segments), moderate (affecting 3–4 limb segments) and severe (affecting more than 5 limb segments) [11]. Bite site temperature (°C) was measured using an infrared digital thermometer (Color Check AC322); the difference between the bite site temperature and the contralateral limb site was calculated. Presence of local bleeding, lymphadenitis and necrosis was also assessed. Systemic signs and symptoms, such as systemic bleeding, signs of acute renal failure, headache, dizziness and vomiting were recorded from patients. Vital signs (blood pressure, heart rate, respiratory rate and axillary temperature) were also assessed. All the clinical information was collected through a standardized clinical registration form. Immediately after clinical examination, a 15 mL blood sample was taken for laboratorial analysis. Tests included leukocyte count (cells/μL), fibrinogen (mg/dL), platelet count (number/μL), hemoglobin (mg/dL), creatine phosphokinase (IU/L), creatine phosphokinase-MB (ng/mL), erythrocyte sedimentation rate (mm/hour), lactate dehydrogenase (IU/L), creatinine (mg/dL), urea (mg/dL), aspartate transaminase (IU/L), alanine transaminase (IU/L), clotting time (in minutes), prothrombin time (in seconds) and C-reactive protein (mg/dL). An aliquot was submitted to an enzyme immunoassay to confirm Bothrops envenoming diagnosis and to determine circulating venom levels in all patients [45]. All the laboratory results were transferred to a standardized registration form.

According to clinical severity, patients were classified using to the Brazilian Health Ministry guidelines [7]: i) mild cases: local pain, local swelling and bruising for Bothrops; ii) moderate cases: local manifestations without necrosis and minor systemic signs (coagulopathy and bleeding, no shock); iii) severe cases: life-threatening snakebite, with severe bleeding, hypotension/shock and/or acute renal failure.

Both groups were submitted to the same local wound care with daily 0.9% saline cleaning. Thirty minutes before antivenom therapy, the intervention group of patients took amoxicillin clavulanate, supervised by a nurse. Twenty minutes after pre-medication with IV hydrocortisone (500 mg), IV cimetidine (300 mg) and oral dexchlorpheniramine (5 mg), antivenom therapy was given to all patients from both arms in a dosage corresponding to the severity grading, according the Brazilian official guidelines [7].

Intervention and control groups were hospitalized for 3 days and returned to the hospital 7 days after admission. A full clinical and laboratory examination were performed 24 hours, 48 hours, 72 hours and 7 days after admission.

Endpoints

The primary efficacy endpoint of this trial was the time free of secondary infection at snakebite site, defined as the presence of cellulitis and/or abscess [38,39], until 7 days after hospital admission. The onset of secondary infection until 48 hours at admission was considered a secondary outcome. Cellulitis was defined by the presence of local inflammation signs (erythema, edema, bruising and pain) with association to fever, leukocytosis, lymphangitis and/or lymphadenitis [46]. An abscess was characterized by individual injuries, floating, presenting purulent secretion or serous-purulent secretion [46,47]. Two independent observers evaluated all the patients and came to a final agreement. Patients clinically diagnosed with secondary infection were additionally evaluated by ultrasonography and a sample collection for microbiology was obtained only in cases evolving to abscess.

After secondary infection diagnosis, amoxicillin clavulanate was interrupted and patient was treated accordingly medical discretion.

Statistical analysis

Before statistical analysis, two independent typists entered information using Epi Info 3.5.1. A study researcher solved disagreements. The primary efficacy analysis was done on all randomized
participants finishing the follow-up (per protocol population). The primary efficacy endpoint, secondary infection-free at 7 days, was analyzed using Kaplan-Meier estimates. A two-sided log-rank test was done over the period using a 5% significance level. Patients that were secondary infection-free at day 7 were censored at this point. The effect of drug use (amoxicillin clavulanate) was assessed as a single block. Relative risk, relative risk reduction, absolute risk reduction and number needed to treat were assessed for primary and secondary outcomes. For the secondary infection risk analysis, at 48 hours and 7 days of follow-up, explanatory variables were grouped in hierarchical blocks [48]. Proximal block was composed by laboratory findings at admission, intermediate block by clinical findings at admission and distal block by demographic and epidemiological variables. Univariate regression analysis was carried out for each block individually. Variables with a significance level of $p < 0.2$ were included in the multivariate analysis by block. All variables with a significance level of $p < 0.05$ in the multivariate analysis by block were thus included in the overall model (all blocks together). Crude odds ratios (OR), adjusted odds ratios (AOR) with their respective confidence intervals were calculated for each hierarchical level and for the overall model. Accuracy of the final model was evaluated by Hosmer-Lemeshow goodness-of-fit test. Where zeros caused problems with computation of the OR and 95% CI, 0.5 was added to all cells [49,50]. Mann-Whitney tests were carried out to assess differences between median of treated and untreated groups. Statistical analyses were performed using the STATA statistical package version 13 (Stata Corp. 2013).

**Results**

**Patients’ characterization**

A total of 345 patients were assessed for eligibility in the study period. From this total, 187 accomplished the inclusion criteria and were randomized, with 93 in the interventional group and 94 in the untreated control group. One patient of the control group was lost to follow up (Fig 1). Enzyme immunoassay confirmed Bothrops envenoming diagnosis in all included patients. Epidemiological characterization showed predominance of males (82.3%), mostly occurring in rural areas (87.1%). The most affected age group was the 21–30 years old (22.6%). The most affected anatomical site was the foot (66.1%). A total of 40.3% of cases were classified as work-related bites and 65.6% of the patients walked after the snakebite. Time elapsed from bite to medical assistance was higher than 3 hours in 42.4% of the cases. Use of topical medicines was informed in 34.4%, oral medicines in 28.5% and tourniquet in 24.7% of the cases (Table 1).

The most frequent manifestations observed at admission were severe pain (46.2%), mild edema (48.4%) and local bleeding (46.8%). The difference of temperature between the bite site and the contralateral site was predominantly $< 1$ °C (51.9%). The most frequent systemic manifestations were headache (26.9%), dizziness (14.5%), gingival bleeding (8.6%), nausea (8.1%) and vomiting (7.0%). Mean axillary temperature was 36.1 °C, mean heart rate was 79.3 bpm, mean respiratory rate was 20 bpm, mean systolic pressure (mmHg) was 129.8 mmHg and mean diastolic pressure (mmHg) was 82.6 mmHg. Snakebites were classified as moderate in 48.9% of the cases (Table 2). No compartmental syndrome, sepsis, gangrene, amputation or death was seen.

Laboratorial characterization revealed mild leukocytosis, hypofibrinogenemia, increased creatine phosphokinase and creatine phosphokinase-MB activities, increased erythrocyte sedimentation rate and mildly increased lactate dehydrogenase activity. Clotting time presented incoagulable in 57.5% of patients. Prothrombin time presented incoagulable in 40.9% of patients. C-reactive protein was $> 6.5$ mg/dL in 18.8% of the cases. Mean blood venom concentration was 50.9 ng/mL (Table 3). No statistical differences were observed between treated
(median = 12) and untreated (median = 6.5) groups when CRP medians were compared (Z = -0.161, p-value = 0.872).

Outcome rates and efficacy estimates

Of the 74 patients with secondary infection, cellulitis was diagnosed in 64 and abscess in 29. Secondary infection rates observed in the intervention and control groups are shown in Table 4. Survival analysis demonstrated that the time from patient admission to the onset of secondary infection was not different between amoxicillin clavulanate treated and control group (Log-rank = 2.23; p = 0.789) (Fig 2). Secondary infection incidence until 7 days after admission was 35.5% in the intervention group and 44.1% in the control group [RR = 0.80 (95%CI = 0.56 to 1.15; p = 0.235)]. Cellulitis rate was 30.1% in the intervention group and 38.7% in the control group [RR = 0.78 (95%CI = 0.52 to 1.16; p = 0.279)]. The abscess rate was 15.1% in the intervention group and 16.1% in the control group [RR = 0.93 (95%CI = 0.48 to 1.82; p = 0.999)].
Table 1. Demographic and epidemiological characteristics of the randomized patients according to the experimental group.

| Characteristics                          | Intervention group (n = 93) | Control group (n = 93) | Total (n = 186) |
|------------------------------------------|----------------------------|------------------------|-----------------|
|                                          | Number | %   | Number | %   | Number | %   |
| Gender                                   |        |     |        |     |        |     |
| Male                                     | 78     | 83.9| 75     | 80.6| 153    | 82.3|
| Female                                   | 15     | 16.1| 18     | 19.4| 33     | 17.7|
| Age group (in years)                     |        |     |        |     |        |     |
| 0–10                                     | 8      | 8.6 | 5      | 5.4 | 13     | 7.0 |
| 11–20                                    | 13     | 14  | 21     | 22.6| 34     | 18.3|
| 21–30                                    | 22     | 23.7| 20     | 21.5| 42     | 22.6|
| 31–40                                    | 11     | 11.8| 16     | 17.2| 27     | 14.5|
| 41–50                                    | 13     | 14  | 10     | 10.8| 23     | 12.4|
| 51–60                                    | 14     | 15  | 14     | 15.1| 28     | 15.1|
| >60                                      | 12     | 12.9| 7      | 7.5 | 19     | 10.2|
| Area of occurrence                       |        |     |        |     |        |     |
| Rural                                    | 80     | 86.0| 82     | 88.2| 162    | 87.1|
| Urban                                    | 13     | 14  | 11     | 11.8| 24     | 12.9|
| Anatomical site of the bite              |        |     |        |     |        |     |
| Upper limbs                              | 1      | 1.1 | 1      | 1.1 | 2      | 1.1 |
| Lower limbs                              | 18     | 19.4| 16     | 17.2| 34     | 18.3|
| Hand                                     | 12     | 12.9| 15     | 16.1| 27     | 14.5|
| Foot                                     | 62     | 66.7| 61     | 65.6| 123    | 66.1|
| Work-related bite                        |        |     |        |     |        |     |
| Yes                                      | 32     | 34.4| 43     | 46.2| 75     | 40.3|
| No                                       | 61     | 65.6| 50     | 53.8| 111    | 59.7|
| Walking after bite (in minutes)          |        |     |        |     |        |     |
| No                                       | 33     | 35.5| 31     | 33.3| 64     | 34.4|
| 5–9                                      | 17     | 18.3| 18     | 19.4| 35     | 18.8|
| 10–29                                    | 24     | 25.8| 24     | 25.8| 48     | 25.8|
| 30–59                                    | 12     | 12.9| 15     | 16.1| 27     | 14.5|
| >60                                      | 7      | 7.6 | 5      | 5.4 | 12     | 6.5 |
| Time elapsed from bite to medical assistance (hours) |        |     |        |     |        |     |
| 0–3                                      | 53     | 57.0| 54     | 58.1| 107    | 57.6|
| 4–6                                      | 22     | 23.7| 27     | 29.0| 49     | 26.3|
| 7–12                                     | 8      | 8.6 | 4      | 4.3 | 12     | 6.5 |
| 13–24                                    | 10     | 10.8| 8      | 8.6 | 18     | 9.7 |
| Previous snakebite history               |        |     |        |     |        |     |
| Yes                                      | 14     | 15.1| 12     | 12.9| 160    | 86.0|
| No                                       | 79     | 84.9| 81     | 87.1| 26     | 14.0|
| Use of topical medicines                 |        |     |        |     |        |     |
| Yes                                      | 32     | 34.4| 32     | 34.4| 64     | 34.4|
| No                                       | 61     | 65.6| 61     | 65.6| 122    | 65.6|
| Use of oral medicines                    |        |     |        |     |        |     |
| Yes                                      | 19     | 20.4| 34     | 36.6| 53     | 28.5|
| No                                       | 74     | 79.6| 59     | 63.4| 133    | 71.5|
| Use of tourniquet                        |        |     |        |     |        |     |
| Yes                                      | 25     | 26.9| 21     | 22.6| 46     | 24.7|
| No                                       | 68     | 73.1| 72     | 77.4| 140    | 75.3|

https://doi.org/10.1371/journal.pntd.0005745.t001
Secondary infection incidence until 48 hours after admission was 22.6% in the intervention group and 36.6% in the control group \[RR = 0.62 \ (95\%CI = 0.38 \text{ to } 0.98; \ p = 0.038)\]. Actually, survival analysis has shown a later onset of secondary infection in the treated group (Fig 2). No late secondary infection (after 7 days of follow-up) was observed.

From the total of 74 patients presenting secondary infections, 88.2% were males and 88.2% occurred in the rural area. The age groups more affected by secondary infections after snake-bite were 31–40 and 51–60 years old, with 20.6% each. Secondary infections were recorded mostly from bites in the foot (61.8%). Infections were secondary to work-related snakebites in 41.2%. Time to medical assistance was less than 3 hours after snakebite in 61.8% of the patients.

| Table 2. Clinical characterization of the randomized participants according to the experimental group. |
|---------------------------------------------------------------|
| Characteristics | Intervention group \(n = 93\) | Control group \(n = 93\) | Total \(n = 186\) |
| Local signs | Number | % | Number | % | Number | % |
| Pain | | | | | | |
| Absent | 12 | 12.9 | 14 | 15.1 | 26 | 14.0 |
| Mild | 13 | 14.0 | 11 | 11.8 | 24 | 12.9 |
| Moderate | 24 | 25.8 | 26 | 28.0 | 50 | 26.9 |
| Severe | 44 | 47.3 | 42 | 45.2 | 86 | 46.2 |
| Edema | | | | | | |
| Mild | 50 | 53.8 | 40 | 43.0 | 90 | 48.4 |
| Moderate | 38 | 40.9 | 44 | 47.3 | 82 | 44.1 |
| Severe | 5 | 5.4 | 9 | 9.7 | 14 | 7.5 |
| Local bleeding | | | | | | |
| Yes | 35 | 37.6 | 52 | 55.9 | 87 | 46.8 |
| No | | | | | | |
| Systemic signs and symptoms | | | | | | |
| Headache | 26 | 28.0 | 24 | 25.8 | 50 | 26.9 |
| Dizziness | 12 | 12.9 | 15 | 16.1 | 27 | 14.5 |
| Gingival bleeding | 9 | 9.7 | 7 | 7.5 | 16 | 8.6 |
| Vomiting | 8 | 8.6 | 5 | 5.4 | 13 | 7.0 |
| Nausea | 7 | 7.5 | 8 | 8.6 | 15 | 8.1 |
| Vital signs | | | | | | |
| Axillary temperature (°C) | 36.0 | 1.5 | 36.2 | 0.6 | 36.1 | 1.1 |
| Heart rate (bpm) | 84.0 | 45.7 | 74.8 | 14.6 | 79.3 | 33.8 |
| Respiratory rate (bpm) | 20.0 | 2.5 | 20.0 | 1.9 | 20.0 | 2.9 |
| Systolic pressure (mmHg) | 130 | 19.6 | 129.6 | 18.2 | 129.8 | 18.9 |
| Diastolic pressure (mmHg) | 82.4 | 12.6 | 82.7 | 15.4 | 82.6 | 14.0 |
| Snakebite clinical classification | | | | | | |
| Mild | 47 | 50.5 | 33 | 35.5 | 80 | 43.0 |
| Moderate | 41 | 44.1 | 50 | 53.8 | 91 | 48.9 |
| Severe | 5 | 5.4 | 10 | 10.8 | 15 | 8.1 |

Secondary infection incidence until 48 hours after admission was 22.6% in the intervention group and 36.6% in the control group \[RR = 0.62 \ (95\%CI = 0.38 \text{ to } 0.98; \ p = 0.038)\]. Actually, survival analysis has shown a later onset of secondary infection in the treated group (Fig 2). No late secondary infection (after 7 days of follow-up) was observed.

From the total of 74 patients presenting secondary infections, 88.2% were males and 88.2% occurred in the rural area. The age groups more affected by secondary infections after snake-bite were 31–40 and 51–60 years old, with 20.6% each. Secondary infections were recorded mostly from bites in the foot (61.8%). Infections were secondary to work-related snakebites in 41.2%. Time to medical assistance was less than 3 hours after snakebite in 61.8% of the patients.
Secondary infections cases. Secondary infections were mostly observed in moderate snakebites (58.8%). Use of local products was made in 35.5% of the secondary infections cases and of tourniquets in 26.5%.

Samples from secondary infection injuries were collected for culture from 11 patients, with 6 positive cases. Microorganisms isolated were *Morganella morganii* (five cases) and *Staphylococcus aureus* (one case).

### Table 3. Laboratorial characterization of the randomized participants according to the experimental group.

| Laboratorial test                  | Intervention group (n = 93) | Control group (n = 93) | Total (n = 186) |
|------------------------------------|-----------------------------|------------------------|-----------------|
|                                    | Mean (SD)/n (%)             | Mean (SD)/n (%)         | Mean (SD)/n (%) |
| Leukocyte count (cells/μL)         | 11,600 (8,900)              | 12,700 (8,700)          | 12,200 (8,800)  |
| Fibrinogen (mg/dL)                 | 204.0 (124.2)               | 178.4 (94.2)            | 174.1 (116.6)   |
| Platelet (number/μL)               | 234,500 (74,400)            | 256,300 (71,200)        | 245,400 (73,400) |
| Hemoglobin (mg/dL)                 | 14.4 (1.3)                  | 14.4 (1.5)              | 14.4 (1.4)      |
| Creatine phosphokinase (IU/L)      | 210.8 (179.4)               | 260.2 (289.6)           | 235.5 (241.5)   |
| Creatine phosphokinase-MB (IU/L)   | 28.6 (33.2)                 | 27.4 (22.1)             | 28.0 (28.1)     |
| Erythrocyte sedimentation rate (mm/hour) | 15.6 (17.6) | 15.9 (17.8)            | 15.8 (17.7)     |
| Lactate dehydrogenase (IU/L)       | 475.2 (598.0)               | 435.9 (258.2)           | 455.6 (459.8)   |
| Creatinine (mg/dL)                 | 1.0 (0.3)                   | 1.0 (0.5)               | 0.9 (0.4)       |
| Urea (mg/dL)                       | 32.7 (11.2)                 | 33.3 (13.6)             | 33.0 (12.4)     |
| Aspartate transaminase (UI/L)      | 29.2 (13.6)                 | 35.0 (25.1)             | 32.1 (20.3)     |
| Alanine transaminase (UI/L)        | 24.2 (19.4)                 | 27.2 (36.9)             | 25.7 (29.5)     |
| Clotting time (minutes)            |                             |                        |                 |
| Normal (4–10)                      | 30 (32.3)                   | 33 (35.5)               | 63 (33.9)       |
| Prolonged (>10)                    | 7 (7.5)                     | 9 (9.7)                 | 16 (8.6)        |
| Incoagulable                       | 56 (60.2)                   | 51 (54.8)               | 107 (57.5)      |
| Prothrombin time (seconds)         |                             |                        |                 |
| Normal (10–14)                     | 4 (4.3)                     | 8 (8.6)                 | 12 (6.5)        |
| Prolonged (>14)                    | 51 (54.8)                   | 47 (50.5)               | 98 (52.6)       |
| Incoagulable                       | 38 (40.9)                   | 38 (40.9)               | 76 (40.9)       |
| C-reactive protein (mg/dL)         |                             |                        |                 |
| <6.5                               | 76 (81.7)                   | 75 (80.7)               | 151 (81.9)      |
| >6.5                               | 17 (18.3)                   | 18 (19.4)               | 35 (18.8)       |
| Blood venom concentration (ng/ml)  | 52.3 (42.0)                 | 49.0 (59.6)             | 50.9 (50.0)     |

Reference values: Leukocytes: 4,000–10,000/mm³; Fibrinogen: 200–400 mg/dL; Platelets: 130,000–400,000/mm³; Hemoglobin: 13.0–16.0 g/dL for males and 12.0–14.0 for females; Creatine phosphokinase: 24–190 IU/L; Creatine phosphokinase-MB: 2–25 IU/L; Erythrocyte sedimentation rate: <10 mm/hour; Lactate dehydrogenase: 211–423 IU/L; Creatinine: 0.5–1.2 mg/dL for adults and 0.3–1.0 mg/dL for children; Urea: 10–45 mg/dL; Aspartate transaminase: 2–38 IU/L; Alanine transaminase: 2–44 IU/L; Clotting time: 4–10 minutes; Prothrombin time: 10–14 seconds; C-reactive protein: <6.5 mg/dL.

https://doi.org/10.1371/journal.pntd.0005745.t003

### Table 4. Secondary infection rates of the patients followed up in the clinical trial, according to the experimental group.

| Outcome                        | Total (n, %) | Intervention group (n, %) | Control group (n, %) | Relative risk |
|--------------------------------|--------------|---------------------------|----------------------|---------------|
| Secondary infection in 7 days   | 74 (39.8)    | 33 (35.5)                 | 41 (44.1)            | 0.80 (0.56 to 1.15) |
| Cellulitis in 7 days            | 64 (34.4)    | 28 (30.1)                 | 36 (38.7)            | 0.78 (0.52 to 1.16) |
| Abscess in 7 days               | 29 (31.9)    | 14 (15.1)                 | 15 (16.1)            | 0.93 (0.48 to 1.82) |
| Secondary infection in 48 hours | 55 (29.6)    | 21 (22.6)                 | 34 (36.6)            | 0.62 (0.38 to 0.98) |

https://doi.org/10.1371/journal.pntd.0005745.t004
Factors associated to secondary infections

Considering proximal variables, secondary infections incidence in 7 days of follow-up was significantly associated to fibrinogen >400 mg/dL [AOR = 3.39 (95%CI = 1.72 to 6.66; p<0.001)], alanine transaminase >44 IU/L [AOR = 2.21 (95%CI = 1.03 to 4.75; p = 0.006)] and C-reactive protein >6.5 mg/L [AOR = 3.90 (95%CI = 1.98 to 7.69; p = <0.001)]. Regarding intermediate variables, moderate [AOR = 11.75 (95%CI = 2.47 to 55.86; p = 0.002)] and severe pain [AOR = 16.97 (95%CI = 2.05 to 340.80; p = 0.001)], moderate [AOR = 3.46 (95%CI = 1.63 to 7.35; p = 0.001)] and severe edema [AOR = 3.78 (95%CI = 1.20 to 11.90; p = 0.023)] and moderate [AOR = 2.52 (95%CI = 1.32 to 4.82; p = 0.005)] and severe snakebites [AOR = 2.80 (95%CI = 0.90 to 8.77; p = 0.076)]. No distal variable was associated to secondary infections incidence (Table 5).

In the final multivariate analysis model, secondary infections incidence in 7 days of follow-up remained significantly associated to fibrinogen >400 mg/dL [AOR = 4.78 (95%CI = 2.17 to 10.55; p<0.001)], alanine transaminase >44 IU/L [AOR = 2.52 (95%CI = 1.06 to 5.98; p = 0.037)], C-reactive protein >6.5 mg/L [AOR = 2.98 (95%CI = 1.40 to 6.35; p = 0.005)], moderate pain [AOR = 24.30 (95%CI = 4.69 to 125.84; p<0.001)] and moderate snakebites [AOR = 2.43 (95%CI = 1.07 to 5.50; p = 0.034)] (Table 6).
Table 5. Factors associated to secondary infection until 7 days of the snakebite patients attended in the hospital in Manaus, 2014 to 2016.

| Variables                          | Secondary Infection Number (%) | Without Secondary Infection Number (%) | Crude OR (IC95%) | p       | AOR (IC95%) | p     |
|------------------------------------|--------------------------------|----------------------------------------|------------------|---------|-------------|-------|
| **Proximal variables**             |                                |                                        |                  |         |             |       |
| Leukocyte counts                   |                                |                                        |                  |         |             |       |
| >10,000/mm³                        | 20 (27.0)                     | 18 (16.1)                              | 1.93 (0.94 to 3.97) | 0.072   | 1.70 (0.73 to 4.00) | 0.222 |
| Fibrinogen                         |                                |                                        |                  |         |             |       |
| >400 mg/dL                         | 49 (66.2)                     | 43 (38.4)                              | 3.15 (1.70 to 3.81) | 0.000   | 3.39 (1.72 to 6.66) | <0.001 |
| Platelet counts                    |                                |                                        |                  |         |             |       |
| <130,000/mm³                       | 3 (4.1)                       | 8 (7.2)                                | 0.55 (0.14 to 2.14) | 0.388   | ...         | ...   |
| Hemoglobin                         |                                |                                        |                  |         |             |       |
| Lower than normal                  | 1 (1.3)                       | 12 (10.7)                              | 0.11 (0.01 to 0.90) | 0.039   | 0.18 (0.02 to 1.45) | 0.108 |
| Creatine phosphokinase             |                                |                                        |                  |         |             |       |
| >190 IU/L                          | 17 (23.0)                     | 15 (13.4)                              | 1.93 (0.90 to 4.16) | 0.093   | 1.61 (0.65 to 3.97) | 0.304 |
| Creatine phosphokinase-MB         |                                |                                        |                  |         |             |       |
| >25 IU/L                           | 15 (20.3)                     | 29 (25.9)                              | 0.73 (0.36 to 1.48) | 0.378   | ...         | ...   |
| Erythrocyte sedimentation rate     |                                |                                        |                  |         |             |       |
| >10 mm/hour                        | 64 (86.5)                     | 89 (79.5)                              | 1.65 (0.74 to 3.71) | 0.223   | ...         | ...   |
| Lactate dehydrogenase              |                                |                                        |                  |         |             |       |
| >423 IU/L                          | 13 (17.6)                     | 24 (21.4)                              | 0.78 (0.37 to 1.65) | 0.519   | ...         | ...   |
| Creatinin                          |                                |                                        |                  |         |             |       |
| Higher than normal                 | 13 (17.6)                     | 14 (12.5)                              | 1.49 (0.66 to 3.39) | 0.339   | ...         | ...   |
| Urea                               |                                |                                        |                  |         |             |       |
| >45 mg/dL                          | 12 (16.2)                     | 16 (14.3)                              | 1.16 (0.51 to 2.62) | 0.719   | ...         | ...   |
| Aspartate transaminase             |                                |                                        |                  |         |             |       |
| >38 IU/L                           | 18 (19.3)                     | 17 (15.2)                              | 1.80 (0.86 to 3.77) | 0.121   | 0.86 (0.29 to 2.52) | 0.783 |
| Alanine transaminase               |                                |                                        |                  |         |             |       |
| >44 IU/L                           | 27 (36.5)                     | 24 (21.4)                              | 2.11 (1.10 to 4.06) | 0.026   | 2.21 (1.03 to 4.75) | 0.042 |
| Clotting time                      |                                |                                        |                  |         |             |       |
| >14 minutes                        | 3 (4.0)                       | 5 (5.4)                                | 0.67 (0.04 to 10.88) | 0.778   | ...         | ...   |
| Prothrombin time                   |                                |                                        |                  |         |             |       |
| >14 seconds                        | 49 (66.2)                     | 79 (74.1)                              | 1.39 (0.74 to 2.64) | 0.321   | ...         | ...   |
| C-reactive protein                 |                                |                                        |                  |         |             |       |
| >6.5 mg/dL                         | 52 (70.3)                     | 42 (37.5)                              | 3.94 (2.10 to 7.38) | <0.001  | 3.90 (1.98 to 7.69) | <0.001 |
| Blood venom level                  |                                |                                        |                  |         |             |       |
| >50 ng/mL                          | 57 (77.0)                     | 96 (85.7)                              | 0.56 (0.26 to 1.19) | 0.132   | 0.55 (0.23 to 1.35) | 0.193 |
| **Intermediate variables**         |                                |                                        |                  |         |             |       |
| Pain                               |                                |                                        |                  |         |             |       |
| No pain                            | 37 (50.0)                     | 95 (84.8)                              | 1                 | ...     | 1           | ...   |
| Mild                               | 12 (16.2)                     | 15 (13.4)                              | 2.05 (0.88 to 4.80) | 0.096   | 1.63 (0.66 to 3.98) | 0.287 |
| Moderate                           | 18 (24.3)                     | 2 (1.8)                                | 23.11 (5.11 to 104.55) | <0.001  | 11.75 (2.47 to55.86) | 0.002 |
| Severe                             | 7 (9.5)                       | 0 (0.0)                                | 38.2 (2.13 to 685.5) | <0.001  | 16.97 (2.05 to340.86) | 0.001 |
| Edema                              |                                |                                        |                  |         |             |       |
| Mild                               | 21 (28.4)                     | 80 (71.5)                              | 1                 | ...     | 1           | ...   |
| Moderate                           | 37 (50.0)                     | 25 (22.3)                              | 5.64 (2.80 to 5.64) | <0.001  | 3.46 (1.63 to7.35) | 0.001 |
| Severe                             | 16 (21.6)                     | 7 (6.2)                                | 8.71 (3.17 to 23.90) | <0.001  | 3.78 (1.20 to11.90) | 0.023 |

(Continued)
### Table 5. (Continued)

| Variables                                         | Secondary infection | Without secondary infection | Crude OR (IC95%) | p   | AOR (IC95%) | p   |
|---------------------------------------------------|---------------------|-----------------------------|------------------|-----|-------------|-----|
| Local bleeding                                    |                     |                             |                  |     |             |     |
| Present                                           | 5 (6.8)             | 2 (1.8)                     | 0.25 (0.47 to 1.33) | 0.140 | 0.28 (0.04 to 1.81) | 0.182 |
| Difference between bite site and the contralateral site temperature (˚C) | | | | | | |
| No difference                                     | 4 (5.4)             | 5 (4.5)                     | 1                | ... | ...         | ... |
| 0.1–0.9                                           | 37 (50.0)           | 59 (53.2)                   | 0.78 (0.20 to 3.11) | 0.729 | ...         | ... |
| 1–1.9                                             | 22 (29.7)           | 23 (20.7)                   | 1.20 (0.28 to 5.24) | 0.808 | ...         | ... |
| 2–2.9                                             | 7 (9.5)             | 17 (15.3)                   | 0.51 (0.11 to 2.50) | 0.411 | ...         | ... |
| >3                                                | 4 (5.4)             | 7 (6.3)                     | 0.71 (0.12 to 4.32) | 0.714 |     |     |
| Classification of the bite                        |                     |                             |                  |     |             |     |
| Mild                                              | 22 (29.7)           | 58 (51.8)                   | 1                | ... | 1           | ... |
| Moderate                                          | 44 (59.5)           | 47 (42.0)                   | 2.46 (1.30 to 4.68) | 0.006 | 2.52 (1.32 to 4.82) | 0.005 |
| Severe                                            | 8 (10.8)            | 7 (6.2)                     | 3.01 (0.98 to 9.30) | 0.055 | 2.80 (0.90 to 8.77) | 0.076 |
| Distal variables                                  |                     |                             |                  |     |             |     |
| Gender                                            |                     |                             |                  |     |             |     |
| Male                                              | 63 (85.1)           | 90 (80.4)                   | 0.71 (0.32 to 1.58) | 0.405 | ...         | ... |
| Area of occurrence                                |                     |                             |                  |     |             |     |
| Rural                                             | 65 (87.8)           | 97 (86.6)                   | 1.03 (0.55 to 1.89) | 0.933 | ...         | ... |
| Age group in years                                |                     |                             |                  |     |             |     |
| 0–10                                              | 5 (6.8)             | 8 (7.2)                     | 1                | ... | ...         | ... |
| 11–20                                             | 10 (13.5)           | 24 (21.4)                   | 0.67 (0.17 to 2.54) | 0.553 | ...         | ... |
| 21–30                                             | 14 (18.9)           | 28 (25.0)                   | 0.80 (0.22 to 2.90) | 0.734 | ...         | ... |
| 31–60                                             | 37 (50.0)           | 41 (36.6)                   | 0.69 (0.19 to 2.34) | 0.569 | ...         | ... |
| >60                                               | 8 (10.8)            | 11 (9.8)                    | 1.63 (0.28 to 4.92) | 0.837 | ...         | ... |
| Bite site                                         |                     |                             |                  |     |             |     |
| Upper limbs                                       | -                   | 2 (1.8)                     | 1                | ... | ...         | ... |
| Lower limbs                                       | 64 (86.5)           | 92 (82.2)                   | ...              | 0.991 | ...         | ... |
| Hand                                              | 9 (12.5)            | 18 (16.0)                   | ...              | 0.991 | ...         | ... |
| Work-related bite                                 |                     |                             |                  |     |             |     |
| Yes                                               | 46 (62.2)           | 65 (58.0)                   | 0.84 (0.46 to 1.54) | 0.575 | ...         | ... |
| Walking after bite                                |                     |                             |                  |     |             |     |
| No                                                | 24 (32.5)           | 40 (35.7)                   | 1                | ... | ...         | ... |
| 5–9 minutes                                       | 10 (13.5)           | 25 (22.3)                   | 0.67 (0.27 to 1.63) | 0.372 | ...         | ... |
| 10–29 minutes                                     | 22 (29.7)           | 26 (23.2)                   | 1.41 (0.66 to 3.02) | 0.376 | ...         | ... |
| 30–59 minutes                                     | 12 (16.2)           | 15 (13.4)                   | 1.33 (0.54 to 3.32) | 0.537 | ...         | ... |
| >60 minutes                                       | 6 (8.1)             | 6 (5.4)                     | 1.67 (0.48 to 5.76) | 0.419 | ...         | ... |
| Time elapsed from bite to medical assistance      |                     |                             |                  |     |             |     |
| 0–3 hours                                         | 40 (54.1)           | 67 (59.8)                   | 1                | ... | ...         | ... |
| 4–6 hours                                         | 22 (29.7)           | 27 (24.1)                   | 1.36 (0.69 to 2.71) | 0.374 | ...         | ... |
| 7–12 hours                                        | 6 (8.1)             | 6 (5.4)                     | 1.68 (0.51 to 5.55) | 0.399 | ...         | ... |
| 13–24 hours                                       | 6 (8.1)             | 12 (10.7)                   | 0.84 (0.29 to 2.41) | 0.742 | ...         | ... |
| Previous history of snakebite                     |                     |                             |                  |     |             |     |
| Yes                                               | 14 (18.9)           | 12 (10.7)                   | 1.94 (0.84 to 4.48) | 0.118 | 1.98 (0.84 to 4.70) | 0.121 |
| Use of topical medicines                          |                     |                             |                  |     |             |     |
| Yes                                               | 23 (31.1)           | 40 (35.7)                   | 0.83 (0.44 to 1.55) | 0.555 | ...         | ... |
| Use of oral medicines                              |                     |                             |                  |     |             |     |

(Continued)
Secondary infections incidence in 48 hours of follow-up was significantly associated to C-reactive protein $>6.5$ mg/L [AOR = 4.28 (95%CI = 1.81 to 10.14; p = 0.001)], moderate [AOR = 5.87 (95%CI = 2.06 to 16.74; p = 0.001)] and severe pain [AOR = 17.89 (95%CI = 1.71 to 186.97; p = 0.016)]. Preemptive amoxicillin clavulanate was protective for secondary infections in 48 hours of follow-up [AOR = 0.42 (95%CI = 0.19 to 0.94; p = 0.034)] (S1 File).

**Discussion**

**Preemptive amoxicillin clavulanate efficacy interpretation**

Antimicrobial schemes for prevention or treatment of secondary infections from snakebites are not based on good evidences from randomized clinical trials [36,37]. Although the Infectious Diseases Society of America (IDSA) guidelines for diagnosis and management of skin and soft-tissue infections indicates amoxicillin clavulanate to reduce complications by prevention of secondary infection from animal bites [38,39], to the best of our knowledge this

### Table 5. (Continued)

| Variables          | Secondary infection Number (%) | Without secondary infection Number (%) | Crude OR (IC95%) | p    | AOR (IC95%) | p    |
|--------------------|-------------------------------|---------------------------------------|-----------------|------|-------------|------|
| Yes                | 23 (31.1)                     | 30 (26.8)                             | 1.23 (0.65 to 2.35) | 0.526|             |      |
| **Use of tourniquet** |                               |                                       |                 |      |             |      |
| Yes                | 21 (28.4)                     | 25 (22.4)                             | 0.73 (0.37 to 1.42) | 0.350|             |      |

**Reference values:** Leukocytes: 4,000–10,000/mm$^3$; Fibrinogen: 200–400 mg/dL; Platelets: 130,000–400,000/mm$^3$; Hemoglobin: 13.0–16.0 g/dL for males and 12.0–14.0 for females; Creatine phosphokinase: 24–190 IU/L; Creatine phosphokinase-MB: 2–25 IU/L; Erythrocyte sedimentation rate: <10 mm/hour; Lactate dehydrogenase: 211–423 IU/L; Creatinine: 0.5–1.2 mg/dL for adults and 0.3–1.0 mg/dL for children; Urea: 10–45 mg/dL; Aspartate transaminase: 2–38 IU/L; Alanine transaminase: 2–44 IU/L; Clotting time: 4–10 minutes; Prothrombin time: 10–14 seconds; C-reactive protein: <6.5 mg/dL.
is the first trial assessing the efficacy of this regimen for snakebites. In this trial, although lower rates of secondary infection was observed in the intervention group such differences between amoxicillin clavulanate treated and control groups over a follow-up of 7 days did not achieve statistical significance. Consistently, analysis of the subgroups of patients who had abscesses or cellulitis presented also not significantly difference in terms of intervention efficacy. A previous study with oral chloramphenicol showed a poor efficacy in preventing secondary infection from Bothrops snakebites [41], although this drug was suggested as a good alternative for the treatment of local infections which may complicate bites by this snake genus [26,51,52]. Accordingly, intravenous chloramphenicol plus gentamicin showed no statistical difference between patients treated and untreated groups in Crotalus snakebites [42]. In a previous study amoxicillin was also used preemptively without any clinical benefit [53]. In general, these trials were not guided by the investigation of the bacterial agents responsible by the snakebite site infection in that area. Indeed, even for routine treatment purposes, secondary infection diagnosis is mostly based only from clinical features without microbiological confirmation followed of antimicrobial resistance profile.

Oral microbiota of snakes comprises a wide range aerobic and anaerobic microorganisms, including Enterobacteriaceae (namelly Morganella spp. and Escherichia coli), Streptococcus, Aeromonas spp., Staphylococcus aureus and Clostridium spp. [20–22]. Few reports of microbiological confirmation of bacteria responsible for snakebites abscesses demonstrated a predominance of aerobics Enterobacteriaceae, mainly Morganella morganii [20,23,24]. The infection may not be necessarily associated to snake’s mouth flora but also to local disorders induced by venom. The significant difference present at 48 hours but not at 7th day could be explained by the contamination between 3rd day and 7th day with origin other than oral microbiota of the snake, such as patient microbiota or iatrogeny. A limitation of this study was the absence of definitive identification of bacteria responsible by the infections for most of the participants. From six bacterial isolations, however, Morganella morganii was present in five snakebite site infections, however no antibiogram was routinely performed. Resistance to β-lactam antibiotics in Morganella species is very common and usually mediated by the presence of chromosomally encoded β-lactamases belonging to the AmpC β-lactamase family. These β-lactamases are typically inducible in the presence of β-lactam antibiotics [54]. As a result, agents such as ampicillin, amoxicillin, and first-generation and some second-generation cephalosporins may be ineffective [55]. This finding highlights the need of previous knowledge of the secondary infections epidemiology as a cornerstone in the preemptive antibiotics trials in snakebites.

Secondary infection incidence until 48 hours after admission had a relative risk reduction of 38.3% for the group using preemptive amoxicillin clavulanate compared to control, showing that antibiotic regimen delayed the onset of secondary infection among treated patients. As the preventive effect did not extend until the end of the follow-up, this delay may represent a severe risk for patients using ineffective preventive antibiotics regimens, because in the absence of signs of local complications patients are usually discharged after 48 hours of hospitalization, and may develop secondary infection without proper medical attention. In the difficulty for riverine and indigenous populations living in remote areas returning to health centers for treatment of this complication, severe clinical conditions such as functional loss, amputation, sepsis and even deaths are possible [28]. Although common in endemic areas, our results point that routine empirical prophylactic use of antibiotics aiming to prevent secondary infection lacks a clearly defined policy, leading to a costly and wasteful inappropriate antibiotic use, and even a risk for the patient [22,40]. Unfortunately due to the limited funding, a double-blinded study was not performed, a possible limitation of the study. Another limitation was the enrollment of patients with less than 24 hours after the bite, what may have selected those less prone to develop secondary infection.
Factors associated to secondary bacterial infection from *Bothrops* snakebites

In *Bothrops* snakebites, studies mostly describe factors associated to systemic complications, such as coagulopathy [11,20], acute renal failure [11,56–59] and death [11,60,61], with extreme age groups and time to medical assistance associated with these poor outcomes [61]. There is scarce information in relation to local complications, especially necrosis [59,62] and amputation [63], associated to anatomical region bitten, systemic bleeding, renal failure, older age and use of tourniquet. Although secondary bacterial infections were observed in around 40% of the *B. atrox* snakebites in the Amazon [13], as confirmed in this work, no epidemiological or clinical predictive marker is known for this complication.

In this work, secondary infections incidence was significantly associated to higher levels fibrinogen, alanine transaminase and C-reactive protein, suggesting these laboratorial markers as auxiliary tools for the diagnosis of secondary infections allied to clinical signs of cellulitis and abscesses. Fibrinogen is an acute-phase protein and its serum concentration may be elevated in inflammatory and infectious conditions associated with vascular damage [64,65]. Even that *B. atrox* metalloproteinases cleave fibrinogen and induces a drop of fibrinogen levels with an increase in fibrin/fibrinogen degradation products (FDP) levels in vivo, with a foremost role in the pathogenesis of coagulopathy and intravascular hemolysis in the acute envenoming [66,67], the intense inflammatory reaction linked to secondary infection persisting after the antivenom therapy may trigger an acute phase reactant response in affected patients. High C-reactive protein paralleling with high fibrinogen in patients with soft-tissue secondary infections [39]. Our study suggests that the proinflammatory profile present in secondary infections from snakebites may be responsible for hepatocellular dysfunction and further elevated alanine transaminases, as previously reported in patients with sepsis and urinary tract infections [68–72]. Cellulitis or abscesses occur mostly in the moderate or severe snakebite cases, as previously reported in southern Brazil [52].

Conclusions and perspectives

The Infectious Diseases Society of America (IDSA) guidelines for diagnosis and management of skin and soft-tissue infections indicate amoxicillin clavulanate to prevent secondary infections from animal bites [38,39]. However, in this study, patients did not benefit from preemptive amoxicillin clavulanate in preventing secondary infection from *Bothrops* snakebites. As a perspective, antimicrobial selection to be used in future clinical trials should be pursued diligently in comprehensive snakebites infection management. Secondary infections incidence was significantly associated to higher levels fibrinogen, alanine transaminase and C-reactive protein, suggesting these laboratorial markers as auxiliary tools for a more accurate diagnosis of secondary infections allied to clinical evaluation.

Supporting information

S1 Checklist. CONSORT checklist.
(DOC)

S1 File. CONSORT flow diagram.
(DOC)

S1 Text. Risk factors for secondary infection in 48 hours of follow-up.
(DOCX)
S1 Dataset. Study database.
(XLSX)

S1 Appendix. Original trial protocol.
(PDF)

S2 Appendix. Ethics approval document.
(PDF)

Acknowledgments

Initially, we thank all patients that participated of this study. We thank the participation of medical and nursing staff of the FMT-HVD hospital, mainly Antônio Magela and Silvio Fragaoso. We also thank all health professionals of the Dermatology ward, medical residents and nursing staff. We had the important contribution of the FMT-HVD clinical laboratory, namely Geraldo Majela, Yonne Francis and Rossiclea Monte. We thank also Diego Britto, Sanmile Holanda, Fernanda Oliveira, Ramisês Santos, Josué Brutus, Ana Paula Damião and Elizandra Nascimento for their technical assistance.

Author Contributions

Conceptualization: Jacqueline A. G. Sachett, Gustavo Adolfo Sierra Romero, Mônica Colombo, Marcus V. G. Lacerda, Wuelton M. Monteiro, Luiz C. L. Ferreira.

Data curation: Jacqueline A. G. Sachett, Iran Mendonça da Silva, Eliane Campos Alves, Sâmella S. Oliveira, Fábio Francesconi do Vale.

Formal analysis: Jacqueline A. G. Sachett, Vanderson S. Sampaio, Gustavo Adolfo Sierra Romero, Marcus V. G. Lacerda, Wuelton M. Monteiro, Luiz C. L. Ferreira.

Funding acquisition: Jacqueline A. G. Sachett, Wuelton M. Monteiro, Luiz C. L. Ferreira.

Investigation: Jacqueline A. G. Sachett, Iran Mendonça da Silva, Eliane Campos Alves, Sâmella S. Oliveira, Fábio Francesconi do Vale, Marcelo Cordeiro dos Santos, Hedylamar Oliveira Marques, Ana Maria Moura da Silva.

Methodology: Jacqueline A. G. Sachett, Gustavo Adolfo Sierra Romero, Marcelo Cordeiro dos Santos, Marcus V. G. Lacerda, Wuelton M. Monteiro, Luiz C. L. Ferreira.

Project administration: Jacqueline A. G. Sachett, Wuelton M. Monteiro, Luiz C. L. Ferreira.

Resources: Jacqueline A. G. Sachett, Ana Maria Moura da Silva, Wuelton M. Monteiro, Luiz C. L. Ferreira.

Supervision: Jacqueline A. G. Sachett, Marcelo Cordeiro dos Santos, Hedylamar Oliveira Marques, Ana Maria Moura da Silva, Wuelton M. Monteiro, Luiz C. L. Ferreira.

Validation: Jacqueline A. G. Sachett, Iran Mendonça da Silva, Vanderson S. Sampaio, Fábio Francesconi do Vale, Hedylamar Oliveira Marques, Ana Maria Moura da Silva, Fan Hui Wen, Marcus V. G. Lacerda, Wuelton M. Monteiro, Luiz C. L. Ferreira.

Visualization: Jacqueline A. G. Sachett, Vanderson S. Sampaio, Wuelton M. Monteiro, Luiz C. L. Ferreira.

Writing – original draft: Jacqueline A. G. Sachett, Vanderson S. Sampaio, Fan Hui Wen, Marcus V. G. Lacerda, Wuelton M. Monteiro, Luiz C. L. Ferreira.
Writing – review & editing: Jacqueline A. G. Sachett, Iran Mendonça da Silva, Eliane Campos Alves, Sâmella S. Oliveira, Vanderson S. Sampaio, Fábio Francesconi do Vale, Gustavo Adolfo Sierra Romero, Marcelo Cordeiro dos Santos, Hedylamar Oliveira Marques, Mônica Colombini, Ana Maria Moura da Silva, Fan Hui Wen, Marcus V. G. Lacerda, Wuelton M. Monteiro, Luiz C. L. Ferreira.

References

1. White J (2000) Bites and stings from venomous animals: a global overview. Ther Drug Monit 22: 65–8. PMID: 10688262

2. Chippaux JP (1998) Snake-bites: Appraisal of the global situation. Bull World Health Organ 76: 515–524. PMID: 9868843

3. Gutierrez JM, Theakston RDG, Warrell D (2006) Confronting the neglected problem of snake bite envenomation: the need for a global partnership. PLoS Med 3: e150. https://doi.org/10.1371/journal.pmed.0030150 PMID: 16729843

4. Kasturiratne A, Wickremasinghe AR, Silva N, Gunawardena NK, Pathmeswaran A, Premaratna R, et al. (2008) The Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional Estimates of Envenomation and Deaths. PLoS Med 5: 1591–1604. https://doi.org/10.1371/journal.pmed.0050218 PMID: 18986210

5. Warrell DA (2010). Snake bite. Lancet 375: 77–88. https://doi.org/10.1016/S0140-6736(09)61754-2 PMID: 20109866

6. Brazilian Ministry of Health. Sistema de Informação de Agravos de Notificação—SINAN. In: Ministério da Saúde [Internet]. 2016 [cited 12 Nov 2016]. Available: http://portalsaude.saude.gov.br/images/pdf/2016/janeiro/20/1-Casos-Ofidismo-2000-2015.pdf

7. Brazilian Ministry of Health. Secretaria de Vigilância em Saúde. Guia de vigilância em saúde [Internet]. Ministério da Saúde, editor. Guia de vigilância em saúde. Brasília; 2014. Available: http://portalsaude.saude.gov.br

8. Moreno E, Queiroz-Andrade M, Lira-da-silva RM, Tavares-Neto J (2005) Clinical and epidemiological characteristics of snakebites in Rio Branco, Acre. Rev Soc Bras Med Trop 2005; 38: 15–21. https://doi.org/10.1590/S0037-86822005000100004 PMID: 15717089

9. Saraiva MG, Oliveira DDS, Filho GMCF, Coutinho LASDA, Guerreiro JV (2012) Epidemiological profile of snake bites in the State of Paraiba, Brazil, 2005 to 2010. Epidemiol Servicos Saude 21: 449–456. https://doi.org/10.5123/S1679-49742012000300010

10. Borges CC, Sadahiro M, Dos-Santos MC (1999) Epidemiological and clinical aspects of snake accidents in the municipalities of the State of Amazonas, Brazil. Rev Soc Bras Med Trop 32: 637–646. Available: http://www.scielo.br/pdf/ibsmt/v32n6/0860.pdf PMID: 10881100

11. Otero R, Gutiérrez J, Beatriz Mesa M, Duque E, Rodríguez O, Luis Arango J, et al. (2002) Complications of Bothrops, Porthidium, and Bothriechis snakebites in Colombia. A clinical and epidemiological study of 39 cases attended in a university hospital. Toxicon 40: 1107–1114. Available: http://www.ncbi.nlm.nih.gov/pubmed/12165312 PMID: 12165312

12. Saborián P, Gonza M, Cambronerio M (1998) Accidente Ofidico en Niños en Costa Rica: Epidemiología y Detección de Factores de Riesgo en el Desarrollo de Absceso y Necrosis. Toxicon 1998; 36: 359–366. PMID: 9620583

13. Souza ARB (2002) Snakebite by Bothrops atrox (Lin. 1758) in the State of Amazonas—Brazil: Study of 212 cases with identified snake. Rev Patol Trop 31: 267–268. Available: http://www.revistas.ufg.br/index.php/iptsp/article/view/14573/9140

14. Alikaabi JM, Al Neyadi M, Al Darei F, Al Mazrooei M, Al Yazedi J, Abdulle AM (2011) Terrestrial snakebites in the South East of the Arabian Peninsula: patient characteristics, clinical presentations, and management. PLoS One 6: e24637. https://doi.org/10.1371/journal.pone.0024637 PMID: 21931788

15. Chen C-M, Wu K-G, Chen C-J, Wang C-M (2011) Bacterial infection in association with snakebite: a 10-year experience in a northern Taiwan medical center. J Microbiol Immunol Infect 44: 456–460. https://doi.org/10.1016/j.jmii.2011.04.011 PMID: 21700517

16. Ozay G, Bosphak M, Ece A, Davutoglu M, Dikici B, Gurkan F, et al. (2005) Clinical characteristics of children with snakebite poisoning and management of complications in the pediatric intensive care unit. Pediatr Int 2005; 47: 669–675. https://doi.org/10.1111/j.1442-200x.2005.02134.x PMID: 16354222

17. David S, Mathaihia S, Christopher S (2012) Mortality predictors of snake bite envenomation in southern India: A ten-year retrospective audit of 533 patients. J Med Toxicol 8: 118–123. https://doi.org/10.1007/s13181-011-0204-0 PMID: 22234395
18. Pierini S V, Warrell DA, Paula A, Theakston RD (1996) High incidence of bites and stings by snakes and other animals among rubber tappers and Amazonian Indians of the Juruá Valley, Acre State, Brazil. Toxicon 34: 225–236. PMID: 8711756

19. Ribeiro LA, Jorge MT (1997) Acidente por serpentes do gênero Bothrops: série de 3.139 casos. Rev Soc Bras Med Trop 30: 475–480. PMID: 9463193

20. Jorge MT, Mendonça JS, Ribeiro LA, Silva MLR, Kusano EJU, Cordeiro CLS (1990) Flora bacteriana da cavidade oral, presas de Bothrops jararaca: possível fonte de infecção no local da picada. Rev Inst Med Trop São Paulo 32: 6–10.

21. Goldstein EJC (1992) Bite wounds and infection. Clin Infect Dis 14: 633–640. Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1562653 PMID: 1562653

22. Garg A, Sujatha S, Garg J, Acharya NS, Parja SC (2009) Wound infections secondary to snakebite. J Infect Dev Ctries 3: 221–223. PMID: 19759478

23. Brazilian Ministry of Health. Fundação Nacional de Saúde. Manual de Diagnóstico e Tratamento de Acidentes por Animais Peçonhentos. Brasília: Fundação Nacional de Saúde; 2001.

24. Jorge MT, Mendonça JS, Ribeiro LA, Cardoso JLC, Silva ML (1987) Bacilos Gram-negativos aeróbios em abscessos por acidente botrópico. Rev Soc Bras Med Trop 20: 55.

25. Bastos HM, Lopes LFL, Gattamorta MA, Matsushima ER (2008) Prevalence of enterobacteria in Bothrops jararaca in São Paulo State: microbiological survey and antimicrobial resistance standards. Acta Sci Biol Sci 30: 321–326. https://doi.org/10.4025/actascibiolsci.v30i3.536

26. Jorge MT, Ribeiro LA, Da Silva MLR, Kusano EJU, Mendonça JS (1994) Microbiological studies of abscesses complicating Bothrops snakebite in humans: A prospective study. Toxicon 32: 743–748. https://doi.org/10.1016/0041-0101(94)90343-3 PMID: 7940580

27. Michael GC, Thacher TD, Shehu MIL (2011) The effect of pre-hospital care for venomous snake bite on outcome in Nigeria. Trans R Soc Trop Med Hyg 105: 95–101. https://doi.org/10.1016/j.trstmh.2010.09.005 PMID: 21035155

28. Wen FH, Monteiro WM, Silva AMM, Tambourgi D V., Silva IM, Sampaio VS, et al. (2015) Snakebites and Scorpion Stings in the Brazilian Amazon: Identifying Research Priorities for a Largely Neglected Problem. PLoS Negl Trop Dis 9: e0003701. https://doi.org/10.1371/journal.pntd.0003701 PMID: 25996940

29. Calvete JJ, Sanz L, Pérez A, Borges A, Vargas AM, Lomonte B, et al. (2011) Snake population venomics and antivenomics of Bothrops atrox: Paedomorphism along its transamazonian dispersal and implications of geographic venom variability on snakebite management. J Proteomics 74: 510–527. https://doi.org/10.1016/j.jprot.2011.01.003 PMID: 21278006

30. López-Lozano JL, Sousa MV, Ricart CAO, Chávez-Olortegui C, Sanchez EF, Muniz EG, et al. (2002) Ontogenetic variation of metalloproteinases and plasma coagulant activity in venoms of wild Bothrops atrox specimens from Amazonian rain forest. Toxicon 40: 997–1006. https://doi.org/10.1016/S0041-0101(02)00096-X PMID: 12076654

31. Assakura MT, Furtado MF, Mandelbaum FR (1992) Biochemical and biological differentiation of the venoms of the lancehead vipers (Bothrops atrox, Bothrops asper, Bothrops marajoensis and Bothrops moojeni ). Comp Biochem Physiol Part B Comp Biochem 102: 727–732. https://doi.org/10.1016/0305-0491(92)90071-X

32. Moreira V, Dos-Santos MC, Nascimento NG, Silva HB, Fernandes CM, D’Impe´rio Lima MR, et al. (2012) Local inflammatory events induced by Bothrops atrox snake venom and the release of distinct classes of inflammatory mediators. Toxicon 60: 12–20. https://doi.org/10.1016/j.toxicon.2012.03.004 PMID: 22465491

33. Otero R, Gutiérrez JM, Nuñez V, Robles A, Estrada R, Segura E, et al. (1996) A randomized double-blind clinical trial of two antivenoms in patients bitten by Bothrops atrox in Colombia. Trans R Soc Trop Med Hyg 90: 696–700. https://doi.org/10.1016/S0035-9203(96)90442-3 PMID: 9015522

34. Pardal PPO, Souza SM, Monteiro MRCC, Fan HW, Cardoso JLC, França FOS, et al. (2004) Clinical trial of two antivenoms for the treatment of Bothrops and Lachesis bites in the north eastern Amazon region of Brazil. Trans R Soc Trop Med Hyg 98: 28–42. Available: http://www.ncbi.nlm.nih.gov/pubmed/14702836 PMID: 14702836

35. Oliveira SS, Sampaio VS, Sachett JAG, Alves EC, Silva VC, Lima JAA, et al. Snakebites in the Brazilian Amazon: Current Knowledge and Perspectives. In: Gopalakrishnakone P., Faiz S.M.A., Ganathanas An Chen-Chang, Vogel Carl-Wilhelm, Denise V. Tambourgi SAS, editor. Clinical Toximology. 1st ed. Holanda: Springer Netherlands; 2016. 22 p.

36. Albuquerque PLMM Jacinto CN, Silva Junior GB Lima JB, Veras MSB Daher EF (2013) Acute kidney injury caused by Crotalus and Bothrops snake venom: a review of epidemiology, clinical manifestations
40. Tagwireyi DD, Ball DE, Nhachi CFB (2001) Routine prophylactic antibiotic use in the management of snakebite. BMC Clin Pharmacol 1: 1–7. https://doi.org/10.1186/1472-6904-1-1

37. Cheng AC, Currie BJ (2004) Venomous Snakebites Worldwide with a Focus on the Australia-Pacific Region: Current Management and Controversies. J Intensive Care Med 19: 259–269. https://doi.org/10.1177/0885066404265799 PMID: 15358944

38. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJC, Gorbach SL, et al. (2014) Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 59: 1–43. https://doi.org/10.1093/cid/ciu218

39. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJC, et al. (2005) Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections. Clin Infect Dis 41: 1373–1406. Available: http://cid.oxfordjournals.org/ https://doi.org/10.1086/497143 PMID: 16231249

40. Tagwireyi DD, Ball DE, Nhachi CFB (2001) Routine prophylactic antibiotic use in the management of snakebite. BMC Clin Pharmacol 1: 1–7. https://doi.org/10.1186/1472-6904-1-1

41. Jorge MT, Malaque C, Ribeiro LA, Fan HW, Cardoso JLC, Nishioka SA, et al. (2004) Failure of chloramphenicol prophyllaxis to reduce the frequency of abscess formation as a complication of envenoming by Bothrops snakes in Brazil: a double-blind randomized controlled trial. Trans R Soc Trop Med Hyg 98: 529–534. https://doi.org/10.1016/j.trstmh.2003.12.009 PMID: 15251401

42. Kerrigan K, Mertz B, Nelson S, Dye J (1997) Antibiotic prophylaxis for pit viper envenomation: prospective, controlled trial. World J Surg 21: 369–373. Available: papers2://publication/uuid/2CEFE28B-F057-4003-94EB-4C29221FF19 PMID: 9143566

43. Brakenbury PH, Mwanga C (1997) A comparative double blind study of amoxycillin/clavulanate vs placebo in the prevention of infection after animal bites. Arch Emerg Med 6: 251–256. PMID: 2692580

44. Huskisson EC (1982) Measurement of pain. J Rheumatol 9: 768–769. PMID: 6184474

45. Colombini M. Reatividade antigênica cruzada entre os venenos de Bothrops atrox e Lachesis muta muta e desenvolvimento de um teste imunoenzimático diferencial para acidentes causados por essas serpentes. Universidade de São Paulo. 2003.

46. Bisno AL, Stevens DL (1996) Streptococcal Infections of Skin and Soft Tissues. N Engl J Med 1996; 334: 240–245. https://doi.org/10.1056/NEJM199601253340407 PMID: 8532002

47. Andrade JG, Pinto RNL, Andrade ALSS, Martelli CMT, Zicker F (1989) Estudo bacteriológico de abscessos causados por picada de serpentes do gênero Bothrops. Rev Inst Med Trop São Paulo 31: 363–367.

48. Victoria CG, Huttly SR, Fuchs SC, Olinoto MT (1997) The role of conceptual frameworks in epidemiological analysis: A Hierarchical Approach. Int J Epidemiol 26: 224–227. https://doi.org/10.1093/ije/26.1.224 PMID: 9126522

49. Pagano M, Gauvreau K. Principles of Biostatistics. 2nd ed. Brooks/Cole; 2000.

50. Deeks J, Higgins J. Statistical algorithms in Review Manager 5 [Internet]. 2010. Available: http://ims.cochrane.org/revman/documentation/Statistical-methods-in-RevMan-5.pdf

51. Jorge MT, Nishioka A, Oliveira RB, Ribeiro LA, Silveira PVP (1998) Aeromonas hydrophila soft-tissue infection as a complication of snake bite: report of three cases. Ann Trop Med Parasitol 92: 213–217. https://doi.org/10.1080/00034989860060067 PMID: 962918

52. Bucaretchi F, Herrera SRF, Hyslop S, Bacarat ECE, Vieira RJ (2001) Snakebites by Bothrops spp in children in Campinas, São Paulo, Brazil. Rev Inst Med Trop São Paulo 43: 329–333. PMID: 11781603

53. Boels D, Hamel JF, Deguigne MB, Harry P (2012) European viper envenomings: Assessment of Viper-fav™ and other symptomatic treatments. Clin Toxicol 50: 189–196. https://doi.org/10.3109/15563650.2012.669695 PMID: 22372786

54. Bush K, Jacoby GA, Medeiros AA (1995) A Functional Classification Scheme for β-Lactamases and Its Correlation with Molecular Structure. Antimicrob Agents Chemother 39: 1211–1233. https://doi.org/10.1128/AAC.39.6.1211 PMID: 7547506

55. Biedenbach DJ, Jones RN, Erwin ME (1993) Interpretive Accuracy of the Disk Diffusion Method for Testing Newer Orally Administered Cephalosporins against Morganella morganii. J Clin Microbiol 31: 2828–2830. PMID: 825998

56. Albuquerque PLMM Silva GB, Jacinto CN Lima JB, Lima CB Amaral YS, et al. (2014) Acute kidney injury after snakebite accident treated in a Brazilian tertiary care centre. Nephrology 19: 764–70. https://doi.org/10.1111/nep.12327 PMID: 25123203

57. Amaral CFS, Rezende NA de, Silva OA da, Ribeiro MMF, Magalhães RA, Reis RJ dos, et al. (1986) Insuficiência renal aguda secundária a acidentes ofídicos botópico e crotálico. Análise de 63 casos. Rev Inst Med Trop Sao Paulo 28: 220–227. https://doi.org/10.1590/S0036-466519868000400003 PMID: 3963305
58. Pinho FMO, Yu L, Burdmann EA (2008) Snakebite-Induced Acute Kidney Injury in Latin America. Semin Nephrol 28: 354–362. https://doi.org/10.1016/j.semnephrol.2008.04.004 PMID: 18620958

59. Ribeiro LA, Gadia R, Jorge MT (2008) Comparison between the epidemiology of accidents and the clinical features of envenoming by snakes of the genus Bot. Rev Soc Bras Med Trop 41: 46–49. PMID: 18368270

60. Ribeiro LA, Albuquerque MJ, Pires de Campos VAF, Katz G, Takaoka NY, Lebrão ML, et al. (1998) Óbitos por serpentes peçonhentas no Estado de São Paulo: avaliação de 43, 1988/93. Rev Assoc Med Bras 44: 312–318. https://doi.org/10.1590/S0104-423019980000400010

61. Feitosa EL, Sampio VS, Salinas JL, Queiroz AM, Silva IM, Gomes AA, et al. (2015) Older Age and Time to Medical Assistance Are Associated with Severity and Mortality of Snakebites in the Brazilian Amazon: A Case-Control Study. PLoS One 10: e0132237. https://doi.org/10.1371/journal.pone.0132237 PMID: 26168155

62. Ribeiro LA, Jorge MT, Lebrão ML (2001) Prognostic factors for local necrosis in Bothrops jararaca (Brazilian pit viper) bites. Trans R Soc Trop Med Hyg 95: 630–634. PMID: 11816436

63. Jorge MT, Ribeiro LA, O’Connell JL (1999) Prognostic factors for amputation in the case of envenoming by snakes of the Bothrops genus (Viperidae). Ann Trop Med Parasitol 93: 401–408. https://doi.org/10.1080/00034989958393 PMID: 10656041

64. Adams R, Passino M, Sachs B, Nuriel T, Akassoglou K (2004) Fibrin mechanisms and functions in nervous system pathology. Mol Interv 4: 163–176. https://doi.org/10.1124/mi.4.3.6 PMID: 15210870

65. Davalos D, Akassoglou K (2012) Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 34: 43–62. https://doi.org/10.1007/s00281-011-0290-8 PMID: 22037947

66. Jacob-Ferreira AL, Menaldo DL, Sartim MA, Riu TB, Dias-Baruffi M, Sampaio S V (2017) Antithrombotic activity of Batroxase, a metalloprotease from Bothrops atrox venom, in a model of venous thrombosis. Int J Biol Macromol 95: 263–267. https://doi.org/10.1016/j.ijbiomac.2016.11.063 PMID: 27876598

67. Jacob-Ferreira AL, Menaldo DL, Bernardes CP, Sartim MA, Angelis CD, Tanus-Santos JE, et al. (2016) Evaluation of the in vivo thrombolytic activity of a metalloprotease from Bothrops atrox venom using a model of venous thrombosis. Toxicicon 109: 18–25. https://doi.org/10.1016/j.toxicon.2015.11.002 PMID: 26556655

68. Szabo G, Romics L, Frendl G (2002). Liver in sepsis and systemic inflammatory response syndrome. Clin Liver Dis 6: 1045–1066. https://doi.org/10.1016/S1089-3284(02)00058-2 PMID: 12516206

69. Koo DJ, Chaudry IH, Wang P (1999) Kupffer cells are responsible for producing inflammatory cytokines and hepatocellular dysfunction during early sepsis. J Surg Res 83: 151–157. https://doi.org/10.1006/jscr.1999.5584 PMID: 10329110

70. Dhainaut JF, Marin N, Mignon A, Vinsonneau C (2001) Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med 29: S42–47. https://doi.org/10.1097/00019995-200107001-00016 PMID: 11445733

71. Campos J, Alende R, Gonzalez-Quintela A (2009) Abnormalities in aminotransferase levels during acute pyelonephritis. Eur J Intern Med 20: e53–e56. https://doi.org/10.1016/j.ejim.2008.08.011 PMID: 19393479

72. Park JY, Ko KO, Lim JW, Cheon EJ, Yoon JM (2013) Increase in Aminotransferase Levels during Urinary Tract Infections in Children. Pediatr Gastroenterol Hepatol Nutr 16: 89–94. https://doi.org/10.5223/pghn.2013.16.2.89 PMID: 24010112